HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix, Inc. (OTCBB:NNLX),
an innovator in the rapid detection of viable bacteria, and
identification and determination of antibiotic resistance/sensitivity of
those bacteria, announces that it is exhibiting at the BioOhio
BioScience Expo and Showcase to be held in Aurora, Ohio on August 5th at
the Bertram Conference Center. Sebastian Faro MD., PhD, a highly
recognized authority on infectious diseases of female reproductive
systems, will be presenting on the NanoLogix N-Assay Multiwell
Microplate Assay during the event. NanoLogix is also a sponsor of the
Expo. There is no charge for admission. Further information is available
by following this link:

The European Patent Office has informed our London and US Patent Law
firms that our European application for the NanoLogix BNP
sandwiched-membrane Petri based detection technology has received an
allowance for grant under the European Patent Convention. The patent
will cover up to 38 member countries, dependent upon NanoLogix’s
election, and significantly enhances the NanoLogix Patent Portfolio. The
BNP technology received patent grants in 2013 in both Japan and Russia
and is currently patent pending in the United States.

NASA

At the American Society for Microbiology (ASM) annual meeting in late
May, NanoLogix’s display booth was visited by NASA. Upon viewing the
NanoLogix Petri plates vacuum packed in nitrogen-charged FlatPacks, the
following comment was made by a NASA scientist: “This is exactly what
we’ve been looking for. We’re sending these up there,” referring to the
International Space Station (ISS).

In early June, at NASA’s request, NanoLogix supplied NASA with a number
of Petri and BNP FlatPacks for their use. The company is currently
awaiting further information from NASA and will release additional news
as appropriate. The qualities that are of interest to NASA are the
robust nature of the Petri dishes packaged in the patented FlatPack with
enhanced durability and resistance to breakage, coupled with the long
term room-temperature shelf life of at least two years, compared to the
competition’s shelf life of 3-1/2 months refrigerated.

Congressional Assistance

NanoLogix is pleased to announce that it is receiving assistance from
Tim Ryan, U.S. Representative for Ohio’s 13th Congressional
District and his staff in exploring potential Federal government uses
for its technologies. NanoLogix management will be traveling to
Washington DC in July for meetings with the Congressman and his staff.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and identification
of microorganisms. In addition to medical, National Defense, and
homeland security applications, NanoLogix technology is applicable in
pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied
microbiology, soil microbiology and bioremediation, microbial
physiology, molecular biology, pharmacology, pharmaco-kinetics, and
antibiotic sensitivity.

This press release contains statements, which may constitute "forward-
looking statements" within the meaning of the Securities Act of 1933 and
the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the
assumptions on which such statements are based. Prospective investors
are cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and uncertainties,
and that actual results may differ materially from those contemplated by
such forward-looking statements. The Company undertakes no obligation to
update or revise forward-looking statements to reflect changed
assumptions, the occurrence of unanticipated events or changes to future
operating results.